Diamond Ranch Foods (PLPL) 0.0215 $PLPL Plandai

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Diamond Ranch Foods (PLPL) 0.0215 $PLPL

Plandai Biotechnology Announces Agreement in Principal for New Clinical Trials to Evaluate Effectiveness of Phytofare in Treating Type II Diabetes
Marketwired - Thu Aug 25, 6:00AM CDT
Planned Mauritius-Based Study to Be Undertaken by North West University South Africa to Determine Impact of Highly Bioavailable Catechins on Blood Sugar Regulation

Plandai Biotechnology to Host Investor Update Conference Call on Friday June 3, 2016 11a.m. ET
Marketwired - Wed Jun 01, 12:29PM CDT
LONDON, UNITED KINGDOM--(Marketwired - Jun 1, 2016) -  Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company", producer of the highly bioavailable Phytofare® catechin complex, today announced it will be hosting an investor update conference call for Friday, June 3, at 11a.m. Eastern Time. The call will feature Board of Directors member and vice president of sales and marketing, Mr. Callum Cottrell-Duffield. The conference call dial-in information is:

Plandai Biotechnology, Inc. Announces New Process That Could Pave the Way to Using Phytofare for Domestic Animals Including Livestock and Pets
Marketwire Canada - Tue May 24, 6:01AM CDT
Revised Trial Expected to Commence June 2016

Plandai Biotechnology, Inc. Announces Vitamin Express to Release New Product Containing Phytofare(R)
Marketwired - Tue May 10, 6:00AM CDT
LONDON, UNITED KINGDOM--(Marketwired - May 10, 2016) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company", producer of the highly bioavailable Phytofare® catechin complex, today announced VitaminExpress, a highly successful health supplement company based in the European Union, is set to release a new product this month, with Phytofare® Catechin Complex as the main ingredient, which will be incorporated into their current product line. Vitamin Express has shipped an astounding 5 million products over the previous 20 years, with customers throughout Western and Eastern Europe.

Plandai Biotechnology, Inc. Announces Record Sales Volume for April
Marketwired - Fri Apr 29, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that April 2016 saw the company sell and ship 425 kilograms of product, representing approximately $60,000 in revenues. In addition, since January, Plandai announced that customers have released to market a total of ten new branded consumer products that contain Phytofare(R), which are being sold in Australia, Western Europe and Africa. Products containing Phytofare(R) should be on shelves in United States as early as May.

Plandai Biotechnology, Inc. Announces First Shipment of Product to USA Customers
Marketwired - Thu Apr 07, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has commenced shipping product to customers in the United States, a first for the London-based company that has thus far primarily sold in Africa and Western Europe. The first order, to be delivered by the end of April, will be formulated into nutriceutical products to be sold in the US and elsewhere by Ultimate Sports Nutrition (www.usn.co.za).

Plandai Biotechnology, Inc. Announces New Distributor to Boost Worldwide Sales
Marketwired - Wed Mar 30, 6:00AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of biopharmaceutical products including the highly bioavailable Phytofare(R) catechin complex, today announced that it has signed a distribution agreement with California-based AIDP Inc. that will enable them to offer Phytofare(R) to their established customer base throughout the world. This agreement will create a way for the company to sell to a wider clientele, including the United States, whereas existing distribution has focused primarily on Europe and Africa.

Plandai Biotechnology, Inc. Announces 2nd Quarter Sales and Gives Forecast for Q3
Marketwired - Mon Mar 28, 3:30PM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that it has sold and shipped over half a ton (640kg) of Phytofare(R) Catechin Complex to customers on four continents during the quarter ending March 31, 2016, its first full quarter of sales. The bulk of these sales were to customers in South Africa and Europe, with initial orders also being filled for Australia and India.

Plandai Biotechnology reports sale of Phytofare in three continents
M2 - Tue Jan 26, 3:06AM CST
Phyto-available extract company Plandai Biotechnology (OTCQBLPL) reported on Monday that Phytofare is being marketed and sold in Africa, Europe and Australia.

Plandai Biotechnology, Inc. Announces Phytofare Sales on Three Continents
Marketwired - Mon Jan 25, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that the Company is actively selling Phytofare(R) in Africa, Europe and Australia, where various customers use Phytofare(R) as the active ingredient in their formulated products. Sales of Phytofare(R) to United States customers are considered imminent, with sales to China anticipated later in the year.

Plandai Biotechnology, Inc. Announces Phytofare(R) Used as Key Ingredient in New Fat Burner Product
Marketwired - Wed Jan 13, 10:08AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that TNT Supplements recently launched their new product, TNT Fat Burner, in the United Kingdom. TNT contains a unique blend of ingredients that have never before been used in tandem, one of which is Plandai's Phytofare(R) catechin complex. Phytofare(R) is a highly bioavailable green tea-based extract that is unique in having clinical data demonstrating ten times greater bioavailability over generic green tea extracts. Furthermore, Phytofare(R) consists of all eight catechins found in green tea, not just ECGC which is found in most weight loss products.

Plandai Biotechnology, Inc. Gives Annual Report of Progress and Provides Projections for 2016
Marketwired - Mon Dec 28, 8:00AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", a producer of highly bioavailable Phytofare(R) Catechin Complex, today reviewed the results and current standings for 2015 and discussed plans for the future as they look to 2016.

Plandai Biotechnology, Inc. Reaches Agreement With Deltamune to Study Commercial Potential of Phytofare in Livestock
Marketwired - Wed Nov 18, 8:01AM CST
Plandai Biotechnology, Inc. (OTCQB: PLPL) ("Plandai" or "the Company", producer of the highly bioavailable Phytofare(R) catechin complex, today announced that its wholly-owned subsidiary, Red Gold (Pty) Ltd., has reached an agreement with Deltamune (Pty) Ltd., a South African-based veterinary research and testing company that also develops and manufactures vaccines for treating Avian Influenza, Infectious Coryza, Egg Drop syndrome and Newcastle disease. Under the terms of the agreement, Deltamune will undertake clinical trials using Plandai's Phytofare(R) Catechin Complex and Citrus Complex to determine the efficacy of the combined all-natural products in helping prevent diseases in poultry. Should the trials prove successful, the parties will move towards executing a production license and distribution agreement.

Plandai Biotechnology signs Phytofare distribution agreement with Bal Pharma Ltd for India
M2 - Wed Oct 28, 5:14AM CDT
Plandai Biotechnology (OTCQBLPL) reported on Tuesday the launch of an exclusive Phytofare distribution Agreement with Bal Pharma, an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients.

Plandai Biotechnology, Inc. Announces Distribution Agreement With Bal Pharma Ltd Covering India
Marketwired - Tue Oct 27, 8:33AM CDT
Plandai Biotechnology, Inc. ("Plandai" or "the Company" (OTCQB: PLPL), producer of the highly bioavailable Phytofare(R), today announced that it has executed an Exclusive Distribution Agreement with Bal Pharma Ltd., an India-based manufacturer and exporter of pharmaceutical finished formulation/bulk drugs and distributor of nutraceuticals ingredients (www.balpharma.com). Under the terms of the agreement, Bal Pharma will use the Company's Phytofare(R) in their finished formulation products while also distributing Phytofare(R) as an active ingredient throughout India. The two-year renewable agreement gives Bal Pharma exclusivity for their territory and fixed pricing based on volume in exchange for defined annual off take.

Plandai Biotechnology, Inc. Announces Distribution Agreement with Coyne Healthcare for Phytofare(R)/Pheriod Finished Product(R)
ACCESSWIRE - Mon Oct 12, 8:54AM CDT
Shipments of Ph(2)(TM) Expected to Commence November 2015

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 4

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 1

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 1

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 3

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 1

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 1

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 0

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading

Top 5 Most Recently Viewed Articles

Compass Therapeutics Pursues Growth with New Public Offering

Updated Category News Views 134

Compass Therapeutics Initiates Public Offering Compass Therapeutics, Inc. (NASDAQ: CMPX), a dynamic and innovative biopharmaceutical company at the forefront of developing antibody-based therapies for cancer treatment, has announced the initiation of an underwritten public offering. This move aims to bolster its financial foundation to facilitate the advancement of its...

Continue Reading
Whirlpool Corporation Declares Substantial Quarterly Dividend

Updated Category News Views 312

Whirlpool Corporation Announces Quarterly Dividend Today, the board of directors of Whirlpool Corporation has declared a quarterly dividend of $1.75 per share on the Company's common stock. This dividend showcases the company's commitment to returning value to its shareholders. It will be payable on June 15, 2025, to stockholders of record at the close of business on May...

Continue Reading
How Tastytrade and Zerohash Transformed Account Funding

Updated Category News Views 312

Tastytrade Enables Instant Stablecoin Funding for Traders Tastytrade, the innovative online brokerage firm designed specifically for self-directed investors, has taken a significant leap forward in enhancing the trading experience. By partnering with Zerohash, they have rolled out an advanced stablecoin account funding option. This cutting-edge method allows traders...

Continue Reading
AKVA Group ASA's Strategic Buyback Program for Shares

Updated Category News Views 155

AKVA Group ASA Initiates Share Buyback Program In a recent announcement, AKVA Group ASA has taken a significant step towards enhancing its shareholder value by initiating a buyback program for up to 60,000 of its own shares. This strategic move is part of the company's plan to reinvest in its workforce through an employee share program, thereby fostering a stronger...

Continue Reading
Nvidia Stock: A Buying Opportunity Amid Market Fluctuations

Updated Category News Views 125

Nvidia Stock Sees Pre-Market Decline Shares of Nvidia Corporation (NASDAQ: NVDA) experienced a decline of 2.01% during the pre-market trading session. This drop followed the company's announcement that it had no revenue from H20 chip sales in China. This news has created some concerns among investors, although industry analysts see potential in the current situation....

Continue Reading